Target-Therapie: Mechanismen
allgemeines
Exon 19, Codon 719, Deletion
Exon 20, Codon 768, 790
Exon 21, Codon 858, 861
Exon 3, Codon 59, 61
Exon 4, Codon 117, 146
Exon 3, Codon 61, 59
Exon 4, Codon 117, 146
| zurück Home | Target-Therapie: Mechanismen | |||
allgemeines | ||||
| Target | Mechanismus | Beispiel | ||
| EGFR | Exon 18, Codon 719 Exon 19, Codon 719, Deletion Exon 20, Codon 768, 790 Exon 21, Codon 858, 861 |
Inhibitor | Cetuximab (Erbitux) | |
| Her2/neu | Inhibitor | Trastuzumab (Herceptin) | ||
| TK, Thyrosin-Kinasen | Inhibitor | Imatinib (Glivec) | ||
| Angiogenese | VEGFR - Hemmer | Bevacizumab (Avastin) | ||
| Proteasom | Inhibitor | Bortezomib (Velcade) | ||
| PARP | Inhibitor | AZD2281 | ||
| KRAS | Exon 2, Codon 12/13 Exon 3, Codon 59, 61 Exon 4, Codon 117, 146 |
NSCLC | ||
| NRAS | Exon 2, Codon 12, 13 Exon 3, Codon 61, 59 Exon 4, Codon 117, 146 |
|||
| BRAF | Codon 600 | |||
| ALK1/EML4-Inversion | ||||
| ROS1-Translokation | Codon 600 | |||
| MEK1, MEK2 | Inhibitor | AZD6244 | ||
| Testsystem | terascreen Pyrosequenzierkit | AZD2281 | ||
| Gerät | Pyromark Q24 MDx-Pyrosequenziergerät | AZD2281 | ||
| Quellen | 1.) Wart et al.: ROS1 expression and translocation in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology 2014;65:187-194 2.) Bubendorf et al.: Testing of ROS1 in non-small-cell lung cancer:a review with recomendations. Virchows Arch 2016;469-503 | |||
| ||||
Impressum Zuletzt geändert am 18.03.2020 20:51